# Indian medicinal phytocompounds for targeting apoptosis and high-penetrance genes in triple-negative breast cancer: an in-silico exploration

**Authors:** Reshmi Kumari, Satarupa Banerjee

PMC · DOI: 10.1186/s12860-025-00548-6 · BMC Molecular and Cell Biology · 2025-07-30

## TL;DR

This study explores how natural plant compounds might target genes involved in aggressive breast cancer, offering a new treatment approach.

## Contribution

The study identifies promising phytochemicals that bind effectively to key cancer-related genes in triple-negative breast cancer.

## Key findings

- Bayogenin showed strong binding to BRCA2 and PALB2 genes, outperforming the drug Olaparib in docking studies.
- Molecular dynamics simulations confirmed the stability of phytochemical-protein complexes over 200 ns.
- Phytochemicals may offer advantages over existing treatments by targeting multiple genes involved in TNBC.

## Abstract

Triple-negative breast cancer (TNBC) presents a significant therapeutic challenge due to its aggressive nature, lack of hormone receptors, and limited targeted treatment options. The complexity of the disease is further compounded by mutations in high-penetrance genes such as BRCA1, BRCA2, and BAX, along with other apoptotic genes involved in tumorigenesis, apoptosis, and drug resistance. Targeting these genes through innovative therapeutic approaches is crucial for improving treatment outcomes. This in-silico study explores the potential of phytochemicals as natural, multi-targeted therapeutic agents against high-penetrance and apoptotic genes implicated in TNBC. Using the IMPPAT 2.0 database, 300 phytochemicals were systematically screened based on their pharmacokinetic properties and toxicity profiles to identify promising candidates. Among them, Bayogenin exhibited strong binding to BRCA2 (-9.3 kcal/mol) and PALB2 (-8.7 kcal/mol), surpassing the FDA-approved drug Olaparib in molecular docking studies. Molecular dynamics simulations over 200 ns further confirmed the stability of these phytochemical-protein complexes, showing consistent root mean square deviation, hydrogen bonding, and free energy profiles. These findings highlight the therapeutic potential of phytochemicals and their possible advantages over existing TNBC treatments. By targeting key molecular pathways, this study provides insights into the development of natural, multi-targeted therapeutic strategies, emphasizing their translational relevance for TNBC therapy.

The online version contains supplementary material available at 10.1186/s12860-025-00548-6.

## Linked entities

- **Genes:** BRCA1 (BRCA1 DNA repair associated) [NCBI Gene 672], BRCA2 (BRCA2 DNA repair associated) [NCBI Gene 675], BAX (BCL2 associated X, apoptosis regulator) [NCBI Gene 581], BRCA2 (BRCA2 DNA repair associated) [NCBI Gene 675], PALB2 (partner and localizer of BRCA2) [NCBI Gene 79728]
- **Diseases:** triple-negative breast cancer (MONDO:0005494)

## Full-text entities

- **Genes:** ABCB1 (ATP binding cassette subfamily B member 1) [NCBI Gene 5243] {aka ABC20, CD243, CLCS, ENPAT, GP170, MDR1}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, BAX (BCL2 associated X, apoptosis regulator) [NCBI Gene 581] {aka BCL2L4}, BIRC5 (baculoviral IAP repeat containing 5) [NCBI Gene 332] {aka API4, EPR-1}, ERBB2 (erb-b2 receptor tyrosine kinase 2) [NCBI Gene 2064] {aka CD340, HER-2, HER-2/neu, HER2, MLN 19, MLN-19}, STK11 (serine/threonine kinase 11) [NCBI Gene 6794] {aka LKB1, PJS, hLKB1}, TP53 (tumor protein p53) [NCBI Gene 7157] {aka BCC7, BMFS5, LFS1, P53, TRP53}, NR4A1 (nuclear receptor subfamily 4 group A member 1) [NCBI Gene 3164] {aka GFRP1, HMR, N10, NAK-1, NGFIB, NP10}, BCL2 (BCL2 apoptosis regulator) [NCBI Gene 596] {aka Bcl-2, PPP1R50}, BRCA1 (BRCA1 DNA repair associated) [NCBI Gene 672] {aka BRCAI, BRCC1, BROVCA1, FANCS, IRIS, PNCA4}, BRCA2 (BRCA2 DNA repair associated) [NCBI Gene 675] {aka BRCC2, BROVCA2, FACD, FAD, FAD1, FANCD}, PIK3CB (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta) [NCBI Gene 5291] {aka P110BETA, PI3K, PI3KBETA, PIK3C1}, HK2 (hexokinase 2) [NCBI Gene 3099] {aka HKII, HXK2}, PALB2 (partner and localizer of BRCA2) [NCBI Gene 79728] {aka BROVCA5, FANCN, PNCA3}, PGP (phosphoglycolate phosphatase) [NCBI Gene 283871] {aka AUM, G3PP, PGPase}, RAD51 (RAD51 recombinase) [NCBI Gene 5888] {aka BRCC5, FANCR, HRAD51, HsRad51, HsT16930, MRMV2}, PTEN (phosphatase and tensin homolog) [NCBI Gene 5728] {aka 10q23del, BZS, CWS1, DEC, GLM2, MHAM}, PRKAA1 (protein kinase AMP-activated catalytic subunit alpha 1) [NCBI Gene 5562] {aka AMPK, AMPK alpha 1, AMPKa1}, CYCS (cytochrome c, somatic) [NCBI Gene 54205] {aka CYC, HCS, THC4}, CASP3 (caspase 3) [NCBI Gene 836] {aka CPP32, CPP32B, SCA-1}, COL11A2 (collagen type XI alpha 2 chain) [NCBI Gene 1302] {aka DFNA13, DFNB53, FBCG2, HKE5, OSMEDA, OSMEDB}, PGR (progesterone receptor) [NCBI Gene 5241] {aka NR3C3, PR}
- **Diseases:** carcinogenic (MESH:D011230), Breast cancer (MESH:D001943), tumorigenesis (MESH:D063646), TNBC (MESH:D064726), cytotoxicity (MESH:D064420), metastasis (MESH:D009362), MDS (MESH:D000092242), Cancer (MESH:D009369), inflammatory (MESH:D007249)
- **Chemicals:** sodium (MESH:D012964), Venetoclax (MESH:C579720), phenolic acids (MESH:C017616), stilbenes (MESH:D013267), flavonoids (MESH:D005419), Ajmaline (MESH:D000404), BRAC2 (-), lignans (MESH:D017705), Olaparib (MESH:C531550), Hydrogen (MESH:D006859), water (MESH:D014867), Tephrosin (MESH:C480848), alpha-Toxicarol (MESH:C501190), Polyphenols (MESH:D059808), Rotenone (MESH:D012402)
- **Species:** Homo sapiens (human, species) [taxon 9606]
- **Cell lines:** MCF-7 — Homo sapiens (Human), Invasive breast carcinoma of no special type, Cancer cell line (CVCL_0031)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12312594/full.md

## Figures

8 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12312594/full.md

## References

36 references — full list in the complete paper: https://tomesphere.com/paper/PMC12312594/full.md

---
Source: https://tomesphere.com/paper/PMC12312594